MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MITTAG, T. W.
Right arrow Articles by MASSA, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MITTAG, T. W.
Right arrow Articles by MASSA, T.

Molecular Pharmacology, Vol 14, 60-68, Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics

Heterogeneity of Acetylcholine Receptors in Denervated Muscle: Interactions of Receptors with immunoglobulin from Patients with Myasthenia Gravis

T. W. MITTAG 1, A. TORMAY 1, and T. MASSA 1

1 Department of Pharmacology, Mount Sinai School of Medicine, City University of New York, New York, New York 10029

The interaction of immunoglobulin G fractions from the sera and thymus glands of patients with myasthenia gravis with acetylcholine receptors from denervated rat muscle was studied using a combination of immunoprecipitation and an assay for binding to concanavalin A-Sepharose. Results showed that myasthenic IgG distinguishes two different agr-bungarotoxin-binding components, each associated with approximately half the total receptor toxin binding capacity. The receptor components can be separated as immune complexes by different properties of binding to concanavalin A and are characterized by different kinetics of toxin binding. The majority of myasthenia gravis sera contain at least two antibodies, directed against determinants on one or both components of the receptor, which do not affect the total binding capacity for agr-bungarotoxin. A few sera contain a third antibody type, which prevents the binding of agr-bungarotoxin to receptors.

Note:
ACKNOWLEDGMENTS We are grateful to G. Genkins, P. Kornfeld, and A. Papatestas for making sera and thymus available for these studies.

Submitted on December 9, 1976
Accepted on August 12, 1977







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1978 by the American Society for Pharmacology and Experimental Therapeutics